Wood A J
Am Heart J. 1984 Oct;108(4 Pt 2):1070-7. doi: 10.1016/0002-8703(84)90583-0.
All of the beta blockers act by antagonizing the actions of the endogenous adrenergic agonists epinephrine and norepinephrine at the beta-adrenergic receptors. However, a number of pharmacologic differences exist between the various agents. Some drugs, such as atenolol and metoprolol, are relatively selective for the beta-1-adrenergic receptors, requiring higher concentrations to block beta-2-adrenergic receptors than are required to block beta-1 receptors. It should be noted, however, that these selective beta blockers all block beta-2 receptors when their concentrations are high enough. When patients with asthma must receive a beta blocker, low doses of a selective drug should be used. Recent studies, however, have suggested that the use of a nonselective beta blocker may be desirable to antagonize some beta-2-mediated metabolic effects, such as hypokalemia, induced by epinephrine. Pindolol is the only beta-receptor antagonist available in the United States with intrinsic sympathomimetic, or partial agonist, activity. Such drugs, because of their partial agonist activity, cause some sympathetic stimulation under conditions of low endogenous sympathetic tone, such as while subjects are at rest in the supine position. Under conditions of higher sympathetic tone, pindolol blocks the effects of the endogenous agonists, producing the characteristic effects of a beta blocker. Membrane-stabilizing activity was first recognized with propranolol, and the value of this property has been a source of controversy ever since, but recent studies suggest that propranolol may induce electrophysiologic effects by mechanisms other than beta blockade. Pharmacokinetic differences between the drugs are also of importance.(ABSTRACT TRUNCATED AT 250 WORDS)
所有β受体阻滞剂均通过拮抗内源性肾上腺素能激动剂肾上腺素和去甲肾上腺素在β肾上腺素能受体上的作用来发挥作用。然而,不同药物之间存在一些药理学差异。某些药物,如阿替洛尔和美托洛尔,对β1肾上腺素能受体具有相对选择性,阻断β2肾上腺素能受体所需的浓度高于阻断β1受体所需的浓度。然而,应该注意的是,当这些选择性β受体阻滞剂的浓度足够高时,它们都会阻断β2受体。当哮喘患者必须接受β受体阻滞剂治疗时,应使用低剂量的选择性药物。然而,最近的研究表明,使用非选择性β受体阻滞剂可能有利于拮抗一些由肾上腺素诱导的β2介导的代谢效应,如低钾血症。吲哚洛尔是美国唯一一种具有内在拟交感活性或部分激动剂活性的β受体拮抗剂。由于这类药物具有部分激动剂活性,在低内源性交感神经张力的情况下,如受试者仰卧休息时,会引起一些交感神经刺激。在较高交感神经张力的情况下,吲哚洛尔会阻断内源性激动剂的作用,产生β受体阻滞剂的典型效应。膜稳定活性最早在普萘洛尔中被发现,自那时起,这种特性的价值一直存在争议,但最近的研究表明,普萘洛尔可能通过β受体阻滞以外的机制诱导电生理效应。药物之间的药代动力学差异也很重要。(摘要截选至250词)